<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597245</url>
  </required_header>
  <id_info>
    <org_study_id>12973</org_study_id>
    <secondary_id>I1F-MC-RHBA</secondary_id>
    <nct_id>NCT01597245</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)</brief_title>
  <acronym>UNCOVER-2</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to
      etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])</measure>
    <time_frame>Week 12</time_frame>
    <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI])</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 were defined as having an improvement of ≥90% in the PASI score compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI 100% (PASI100)</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI100 were defined as having an improvement of 100% in the PASI score compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 60</measure>
    <time_frame>Week 60</time_frame>
    <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable&quot;. The number and percentage of participants achieving an Itch NRS ≥4 point reduction from baseline were presented by treatment group for participants who had a baseline Itch NRS ≥4. Describes worst level of itching in past 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much); and &quot;not relevant&quot; and unanswered responses were scored as &quot;0.&quot; Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. A 5-point change from baseline is considered clinically relevant. Least Squares (LS) Mean change from baseline was calculated using mixed model repeated measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nail Psoriasis Severity Index (NAPSI)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. The fingernail bed and fingernail matrix are each divided into quadrants. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. The NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80 with higher scores indicating more severe Ps. LS mean change from baseline in NAPSI score was calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Psoriasis Scalp Severity Index (PSSI) Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total scores range from 0 (less severity) to 72 (more severity), with lower scores indicating less severity. LS mean change from baseline in PSSI score was calculated using MMRM with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using MMRM with baseline BSA as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance [initial, middle and late insomnia or hypersomnia], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean change from baseline in total QIDS-SR16 score was calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score * 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean change from baseline in SF-36 score was calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment (PatGA) of Disease Severity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The Patient's Global Assessment of Disease Severity is a single-item patient reported outcome measure on which participants are asked to rate by circling a number on a 0 to 5 NRS the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been. LS mean change from baseline in patient's global assessment of disease severity score was calculated using (MMRM) with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75) or 100% (PPASI100) Improvement</measure>
    <time_frame>Week 12</time_frame>
    <description>The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 75%, or of 100%, respectively, in the PPASI scores compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Ixekizumab Antibodies</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the # of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1224</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg etanercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for ixekizumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg ixekizumab Dosing Regimen</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 1</arm_group_label>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 2</arm_group_label>
    <arm_group_label>80 mg ixekizumab Dosing Regimen 3</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg etanercept</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>50 mg etanercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo for ixekizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic plaque
             psoriasis for at least 6 months prior to first dose of study drug

          -  At least 10% Body Surface Area (BSA) of psoriasis at screening and at first dose of
             study drug

          -  Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and
             Severity Index (PASI) score of at least 12 at screening and at first dose of study
             drug

          -  Candidate for phototherapy and/or systemic therapy

          -  Men must agree to use a reliable method of birth control or remain abstinent during
             the study

          -  Women must agree to use reliable birth control or remain abstinent during the study
             and for at least 12 weeks after stopping treatment

        Exclusion Criteria:

          -  Pustular, erythrodermic, and/or guttate forms of psoriasis

          -  History of drug-induced psoriasis

          -  Prior use of etanercept

          -  Clinically significant flare of psoriasis during the 12 weeks prior to randomization

          -  Concurrent or recent use of any biologic agent

          -  Received non-biologic systemic psoriasis therapy or phototherapy (including psoralens
             and ultraviolet A [PUVA], ultraviolet B [UVB]) within the previous 4 weeks; or had
             topical psoriasis treatment within the previous 2 weeks prior to randomization

          -  Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks
             prior to randomization and during the study

          -  Have participated in any study with interleukin 17 (IL-17) antagonists, including
             ixekizumab

          -  Serious disorder or illness other than plaque psoriasis

          -  Serious infection within the last 3 months

          -  Breastfeeding or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phillip</city>
        <state>Australian Capital Territory</state>
        <zip>02606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>02000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Woolloogabba</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hectorville</city>
        <state>South Australia</state>
        <zip>05073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vienna</city>
        <zip>A1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3G 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 3T6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boulogne</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chambray Les Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rouen</city>
        <zip>76036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Giessen</city>
        <zip>35390</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osnabrück</city>
        <zip>49078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Witten</city>
        <zip>58453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kielce</city>
        <zip>25-317</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Opole</city>
        <zip>48-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>700381</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timisoara</city>
        <zip>300077</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alcorcón</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Palmas</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dundee</city>
        <state>Angus</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Hampstead</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lanarkshire</city>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scunthorpe</city>
        <zip>DN15 7BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <results_first_submitted>April 20, 2016</results_first_submitted>
  <results_first_submitted_qc>August 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2016</results_first_posted>
  <disposition_first_submitted>January 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>January 16, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2015</disposition_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who received ixekizumab (ixe) and classified as responder (Resp, sPGA 0/1) in Induction (IND) re-randomized to receive 80 mg ixe Q4W, Q12W or placebo (PBO) in Maintenance (MAIN) (Primary Population [Pop]). Non-responders (Non-Resp, sPGA &gt;1) in IND received 80 mg ixe Q4W, PBO Resp, ETN Resp received PBO in MAIN (Secondary Pop).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo- Induction Period</title>
          <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="P2">
          <title>50 mg Etanercept (ETN) - Induction Period</title>
          <description>50 milligrams (mg) ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
        </group>
        <group group_id="P3">
          <title>Ixe Q4W - Induction Period</title>
          <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W:Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="P4">
          <title>Ixe Q2W - Induction Period</title>
          <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12</description>
        </group>
        <group group_id="P5">
          <title>Ixe/Placebo- Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P6">
          <title>Ixe/Ixe Q12W - Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection every 12 weeks (Q12W) up to and including Week 56. To maintain blinding with Q4W dose regimen, Placebo for ixe given as 1 SC injection at every 4 weeks from Week 16 through Week 56.</description>
        </group>
        <group group_id="P7">
          <title>Ixe/Ixe Q4W - Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P8">
          <title>Placebo Resp/Placebo - Maintenance Period Secondary Pop</title>
          <description>Participants who received placebo during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P9">
          <title>Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received placebo in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P10">
          <title>ETN Resp/Placebo Maintenance Period Secondary Pop</title>
          <description>Participants who received ETN during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P11">
          <title>ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received ETN in Induction Period (Weeks 0 to 12) and classified as non-responders were administered 2 SC injections of placebo at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P12">
          <title>Ixe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary Pop</title>
          <description>Participants who received 80 mg ixe Q4W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="P13">
          <title>Ixe Q2W Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received 80 mg ixe Q2W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period (Week 0 - Week 12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="358"/>
                <participants group_id="P3" count="347"/>
                <participants group_id="P4" count="351"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="357"/>
                <participants group_id="P3" count="347"/>
                <participants group_id="P4" count="350"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="333">1 participant randomized to maintenance period but did not receive a dose in the maintenance period.</participants>
                <participants group_id="P3" count="328"/>
                <participants group_id="P4" count="342">2 participants discontinued after IND completion and prior to randomizing into maintenance period.</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period (Week 12 to Week 60)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="176"/>
                <participants group_id="P6" count="181"/>
                <participants group_id="P7" count="187"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="155"/>
                <participants group_id="P10" count="132"/>
                <participants group_id="P11" count="200"/>
                <participants group_id="P12" count="75"/>
                <participants group_id="P13" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received One Dose</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="176"/>
                <participants group_id="P6" count="181"/>
                <participants group_id="P7" count="187"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="155"/>
                <participants group_id="P10" count="132"/>
                <participants group_id="P11" count="200"/>
                <participants group_id="P12" count="75"/>
                <participants group_id="P13" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="92"/>
                <participants group_id="P7" count="150"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="135"/>
                <participants group_id="P10" count="14"/>
                <participants group_id="P11" count="178"/>
                <participants group_id="P12" count="56"/>
                <participants group_id="P13" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="159"/>
                <participants group_id="P6" count="89"/>
                <participants group_id="P7" count="37"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="118"/>
                <participants group_id="P11" count="22"/>
                <participants group_id="P12" count="19"/>
                <participants group_id="P13" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>On study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapsed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="148"/>
                <participants group_id="P6" count="80"/>
                <participants group_id="P7" count="21"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="111"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="10"/>
                <participants group_id="P13" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo - Induction Period</title>
          <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="B2">
          <title>50 mg ETN - Induction Period</title>
          <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
        </group>
        <group group_id="B3">
          <title>Ixe Q4W - Induction Period</title>
          <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W: Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="B4">
          <title>Ixe Q2W - Induction Period</title>
          <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
            <count group_id="B2" value="358"/>
            <count group_id="B3" value="347"/>
            <count group_id="B4" value="351"/>
            <count group_id="B5" value="1224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="12.13"/>
                    <measurement group_id="B2" value="45.3" spread="12.79"/>
                    <measurement group_id="B3" value="45" spread="13.53"/>
                    <measurement group_id="B4" value="44.5" spread="13.27"/>
                    <measurement group_id="B5" value="45.0" spread="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="130"/>
                    <measurement group_id="B5" value="403"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="244"/>
                    <measurement group_id="B4" value="221"/>
                    <measurement group_id="B5" value="821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="271"/>
                    <measurement group_id="B4" value="274"/>
                    <measurement group_id="B5" value="954"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="315"/>
                    <measurement group_id="B4" value="330"/>
                    <measurement group_id="B5" value="1125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Static Physician Global Assessment (sPGA)</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. The sPGA is recommended as an endpoint to use to assess efficacy in the treatment of Ps (EMEA 2004). Overall lesions are categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's Ps is assessed at a given time point on a 6-point scale in which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate; 4 = severe, 5 = very severe.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>sPGA = 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="166"/>
                    <measurement group_id="B4" value="178"/>
                    <measurement group_id="B5" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sPGA = 4,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="173"/>
                    <measurement group_id="B5" value="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Participants Achieving Psoriasis Area and Severity Index (PASI) Score</title>
          <description>PASI is another accepted primary efficacy measurement for this phase of development of Ps treatments. The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.57" spread="8.366"/>
                    <measurement group_id="B2" value="19.07" spread="6.701"/>
                    <measurement group_id="B3" value="20.04" spread="6.962"/>
                    <measurement group_id="B4" value="19.35" spread="7.339"/>
                    <measurement group_id="B5" value="19.63" spread="7.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Dermatology-Specific Quality of Life Index (DLQI) Total Score</title>
          <description>DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered (&quot;not relevant&quot;) responses were scored as &quot;0.&quot; Total scores range from 0 to 30, with higher score indicating greater quality of life impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="7.24"/>
                    <measurement group_id="B2" value="12.7" spread="7.03"/>
                    <measurement group_id="B3" value="11.6" spread="6.65"/>
                    <measurement group_id="B4" value="12.4" spread="6.86"/>
                    <measurement group_id="B5" value="12.3" spread="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Nail Psoriasis Severity Index (NAPSI) Total Score</title>
          <description>The NAPSI scale evaluates Ps severity in the fingernail bed and fingernail matrix with each divided into quadrants. Scores range from 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80. Higher scores indicate more severe Ps.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.62" spread="20.937"/>
                    <measurement group_id="B2" value="30.44" spread="20.648"/>
                    <measurement group_id="B3" value="23.70" spread="18.696"/>
                    <measurement group_id="B4" value="26.27" spread="20.388"/>
                    <measurement group_id="B5" value="26.97" spread="20.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score</title>
          <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="15.24"/>
                    <measurement group_id="B2" value="20.0" spread="15.19"/>
                    <measurement group_id="B3" value="20.8" spread="15.63"/>
                    <measurement group_id="B4" value="19.5" spread="14.85"/>
                    <measurement group_id="B5" value="20.2" spread="15.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Body Surface Area (BSA) Total Score</title>
          <description>BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participant's hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="18.12"/>
                    <measurement group_id="B2" value="25.3" spread="15.50"/>
                    <measurement group_id="B3" value="27.0" spread="17.23"/>
                    <measurement group_id="B4" value="25.1" spread="15.82"/>
                    <measurement group_id="B5" value="26.0" spread="16.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Quick Inventory of Depressive Symptomatology Self Report 16 items (QIDS-SR16) Score</title>
          <description>QIDS-SR16 is a participant-administered, 16-item instrument assesses the existence and severity of symptoms of depression. A participant is asked a statement relating to the way they have felt for the past 7 days and rate on a 4-point scale: 0 (best) to 3 (worst). The sum of the domains [sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance, decrease/increase in appetite/weight, and psychomotor agitation/retardation] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="4.14"/>
                    <measurement group_id="B2" value="4.5" spread="4.07"/>
                    <measurement group_id="B3" value="4.4" spread="4.04"/>
                    <measurement group_id="B4" value="4.6" spread="3.84"/>
                    <measurement group_id="B5" value="4.5" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) Total Score</title>
          <description>The (WPAI-PSO) is a 6-item instrument to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains: absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score * 100 and ranges from 0-100; greater scores indicate greater impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Absenteeism Score (n=106, 227, 232, 238, 803)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="16.61"/>
                    <measurement group_id="B2" value="3.7" spread="15.24"/>
                    <measurement group_id="B3" value="4.6" spread="17.65"/>
                    <measurement group_id="B4" value="7.3" spread="22.15"/>
                    <measurement group_id="B5" value="5.1" spread="18.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active Impairment Score (n=166,356,346,347,1215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" spread="28.87"/>
                    <measurement group_id="B2" value="31.3" spread="29.04"/>
                    <measurement group_id="B3" value="29.4" spread="29.28"/>
                    <measurement group_id="B4" value="31.7" spread="29.64"/>
                    <measurement group_id="B5" value="30.7" spread="29.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism Score (n=109, 239, 243,248, 839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="26.19"/>
                    <measurement group_id="B2" value="21.2" spread="25.42"/>
                    <measurement group_id="B3" value="22.3" spread="24.77"/>
                    <measurement group_id="B4" value="24.2" spread="25.80"/>
                    <measurement group_id="B5" value="22.8" spread="25.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Productivity Loss (n=105,227,231,237,800)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="28.11"/>
                    <measurement group_id="B2" value="22.3" spread="26.52"/>
                    <measurement group_id="B3" value="24.6" spread="27.41"/>
                    <measurement group_id="B4" value="27.7" spread="29.19"/>
                    <measurement group_id="B5" value="25.0" spread="27.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Short form (36 Items) Health Survey SF-36 Total Score</title>
          <description>The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the Physical Component Score (PCS) and Mental Component Score (MCS) scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Physical Summary Score (n=166,354,345,350,1215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7094" spread="9.5043"/>
                    <measurement group_id="B2" value="47.5268" spread="9.0729"/>
                    <measurement group_id="B3" value="47.6231" spread="8.9693"/>
                    <measurement group_id="B4" value="47.6996" spread="9.0332"/>
                    <measurement group_id="B5" value="47.6289" spread="9.0814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Summary Score (n=166, 354, 345, 350, 1215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7889" spread="10.6183"/>
                    <measurement group_id="B2" value="48.7097" spread="10.6546"/>
                    <measurement group_id="B3" value="49.0131" spread="10.9087"/>
                    <measurement group_id="B4" value="47.7140" spread="11.6686"/>
                    <measurement group_id="B5" value="48.3832" spread="11.0234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline in Patient's Global Assessment (PatGA) Total Score</title>
          <description>The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis &quot;today&quot; by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="0.92"/>
                    <measurement group_id="B2" value="4.0" spread="0.96"/>
                    <measurement group_id="B3" value="4.1" spread="0.90"/>
                    <measurement group_id="B4" value="4.1" spread="0.91"/>
                    <measurement group_id="B5" value="4.0" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</title>
        <description>The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of “0” or “1” with at least a 2-point improvement from baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections Q2W up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Etanercept (ETN) - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W: Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])</title>
          <description>The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of “0” or “1” with at least a 2-point improvement from baseline.</description>
          <population>All randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="36.0"/>
                    <measurement group_id="O3" value="72.9"/>
                    <measurement group_id="O4" value="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.</description>
          <population>All randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="41.6"/>
                    <measurement group_id="O3" value="77.5"/>
                    <measurement group_id="O4" value="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])</title>
        <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant’s Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections Q2W up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W: Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant’s Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
          <population>All randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="32.3"/>
                    <measurement group_id="O4" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI])</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 were defined as having an improvement of ≥90% in the PASI score compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI])</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 were defined as having an improvement of ≥90% in the PASI score compared to baseline.</description>
          <population>All randomized participants analyzed according to the treatment to which they were assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="18.7"/>
                    <measurement group_id="O3" value="59.7"/>
                    <measurement group_id="O4" value="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI 100% (PASI100)</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI100 were defined as having an improvement of 100% in the PASI score compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI 100% (PASI100)</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI100 were defined as having an improvement of 100% in the PASI score compared to baseline.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="347"/>
                <count group_id="O4" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="30.8"/>
                    <measurement group_id="O4" value="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 60</title>
        <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
        <time_frame>Week 60</time_frame>
        <population>All randomized participants who had sPGA score of (0,1) at Week 12, were re-randomized at Week 12 and received at least 1 dose of study treatment in the Maintenance Dosing Period. Participants who did not meet the clinical response criteria or had missing data at Week 60 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixe/Placebo- Maintenance Period Primary Pop</title>
            <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
          </group>
          <group group_id="O2">
            <title>Ixe/Ixe Q12W - Maintenance Period Primary Pop</title>
            <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection every 12 weeks (Q12W) up to and including Week 56. To maintain blinding with Q4W dose regimen, placebo for ixe given as 1 SC injection at every 4 weeks from Week 16 through Week 56 .</description>
          </group>
          <group group_id="O3">
            <title>Ixe/Ixe Q4W - Maintenance Period Primary Pop</title>
            <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 60</title>
          <description>The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).</description>
          <population>All randomized participants who had sPGA score of (0,1) at Week 12, were re-randomized at Week 12 and received at least 1 dose of study treatment in the Maintenance Dosing Period. Participants who did not meet the clinical response criteria or had missing data at Week 60 were considered non-responders for Non-Responder Imputation (NRI) analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="40.9"/>
                    <measurement group_id="O3" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline</title>
        <description>The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable&quot;. The number and percentage of participants achieving an Itch NRS ≥4 point reduction from baseline were presented by treatment group for participants who had a baseline Itch NRS ≥4. Describes worst level of itching in past 24 hours.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned and had Itch NRS ≥4 at baseline. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline</title>
          <description>The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing &quot;no itch&quot; and 10 representing &quot;worst itch imaginable&quot;. The number and percentage of participants achieving an Itch NRS ≥4 point reduction from baseline were presented by treatment group for participants who had a baseline Itch NRS ≥4. Describes worst level of itching in past 24 hours.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned and had Itch NRS ≥4 at baseline. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="293"/>
                <count group_id="O4" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="57.8"/>
                    <measurement group_id="O3" value="76.8"/>
                    <measurement group_id="O4" value="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])</title>
        <description>DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much); and &quot;not relevant&quot; and unanswered responses were scored as &quot;0.&quot; Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. A 5-point change from baseline is considered clinically relevant. Least Squares (LS) Mean change from baseline was calculated using mixed model repeated measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned and who had baseline and at least 1 post-baseline DLQI measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])</title>
          <description>DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much); and &quot;not relevant&quot; and unanswered responses were scored as &quot;0.&quot; Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. A 5-point change from baseline is considered clinically relevant. Least Squares (LS) Mean change from baseline was calculated using mixed model repeated measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned and who had baseline and at least 1 post-baseline DLQI measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="338"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.36"/>
                    <measurement group_id="O2" value="-7.7" spread="0.25"/>
                    <measurement group_id="O3" value="-9.4" spread="0.25"/>
                    <measurement group_id="O4" value="-10.4" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI)</title>
        <description>The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. The fingernail bed and fingernail matrix are each divided into quadrants. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. The NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80 with higher scores indicating more severe Ps. LS mean change from baseline in NAPSI score was calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned; and had fingernail Ps involvement at baseline and at least 1 post-baseline NAPSI measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nail Psoriasis Severity Index (NAPSI)</title>
          <description>The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. The fingernail bed and fingernail matrix are each divided into quadrants. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. The NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80 with higher scores indicating more severe Ps. LS mean change from baseline in NAPSI score was calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned; and had fingernail Ps involvement at baseline and at least 1 post-baseline NAPSI measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="215"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="1.162"/>
                    <measurement group_id="O2" value="-5.34" spread="0.835"/>
                    <measurement group_id="O3" value="-7.39" spread="0.843"/>
                    <measurement group_id="O4" value="-8.60" spread="0.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Psoriasis Scalp Severity Index (PSSI) Score</title>
        <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total scores range from 0 (less severity) to 72 (more severity), with lower scores indicating less severity. LS mean change from baseline in PSSI score was calculated using MMRM with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned; and had scalp Ps involvement at baseline and at least 1 post-baseline PSSI measurement. Missing data was imputed by last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Psoriasis Scalp Severity Index (PSSI) Score</title>
          <description>The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (&lt;10%) to 6 (90%-100%) with a total scores range from 0 (less severity) to 72 (more severity), with lower scores indicating less severity. LS mean change from baseline in PSSI score was calculated using MMRM with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned; and had scalp Ps involvement at baseline and at least 1 post-baseline PSSI measurement. Missing data was imputed by last observation carried forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="316"/>
                <count group_id="O3" value="307"/>
                <count group_id="O4" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="0.73"/>
                    <measurement group_id="O2" value="-14.8" spread="0.50"/>
                    <measurement group_id="O3" value="-18.5" spread="0.51"/>
                    <measurement group_id="O4" value="-18.7" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis</title>
        <description>The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using MMRM with baseline BSA as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned; and had at least 1 post-baseline BSA measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis</title>
          <description>The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using MMRM with baseline BSA as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned; and had at least 1 post-baseline BSA measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="342"/>
                <count group_id="O4" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.05"/>
                    <measurement group_id="O2" value="-12.4" spread="0.72"/>
                    <measurement group_id="O3" value="-20.3" spread="0.72"/>
                    <measurement group_id="O4" value="-20.6" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score</title>
        <description>The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance [initial, middle and late insomnia or hypersomnia], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean change from baseline in total QIDS-SR16 score was calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned, and had baseline and at least 1 post baseline QIDS-SR16 measurement. Missing data was imputed by last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score</title>
          <description>The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance [initial, middle and late insomnia or hypersomnia], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean change from baseline in total QIDS-SR16 score was calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned, and had baseline and at least 1 post baseline QIDS-SR16 measurement. Missing data was imputed by last observation carried forward (LOCF).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="342"/>
                <count group_id="O3" value="334"/>
                <count group_id="O4" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.21"/>
                    <measurement group_id="O2" value="-0.3" spread="0.15"/>
                    <measurement group_id="O3" value="-0.7" spread="0.15"/>
                    <measurement group_id="O4" value="-0.9" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.150</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)</title>
        <description>The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score * 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned, and had baseline and at least 1 post baseline WPAI-PSO measurement. Missing data was imputed by last observation carried forward ( LOCF ).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)</title>
          <description>The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score * 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned, and had baseline and at least 1 post baseline WPAI-PSO measurement. Missing data was imputed by last observation carried forward ( LOCF ).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="342"/>
                <count group_id="O3" value="332"/>
                <count group_id="O4" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absenteeism (n=87, 199, 204, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.83"/>
                    <measurement group_id="O2" value="-3.7" spread="0.55"/>
                    <measurement group_id="O3" value="-3.2" spread="0.54"/>
                    <measurement group_id="O4" value="-3.9" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity Impairment Score (n=160, 342, 332, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.46"/>
                    <measurement group_id="O2" value="-16.6" spread="1.00"/>
                    <measurement group_id="O3" value="-22.6" spread="1.02"/>
                    <measurement group_id="O4" value="-25.8" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism Score (n=94, 217, 226, 232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.59"/>
                    <measurement group_id="O2" value="-12.4" spread="1.05"/>
                    <measurement group_id="O3" value="-18.5" spread="1.03"/>
                    <measurement group_id="O4" value="-18.2" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work Productivity Loss Score (n=86, 199, 203, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.80"/>
                    <measurement group_id="O2" value="-13.7" spread="1.18"/>
                    <measurement group_id="O3" value="-19.3" spread="1.18"/>
                    <measurement group_id="O4" value="-19.5" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absenteeism Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Absenteeism Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Absenteeism Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity Impairment Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Activity Impairment Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Activity Impairment Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Presenteeism Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Presenteeism Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Presenteeism Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Work Productivity Loss Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Work Productivity Loss Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Work Productivity Loss Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
        <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean change from baseline in SF-36 score was calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned, and had baseline and at least 1 post baseline SF-36 measurement. Missing data was imputed by last observation carried forward ( LOCF ).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
          <description>The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean change from baseline in SF-36 score was calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned, and had baseline and at least 1 post baseline SF-36 measurement. Missing data was imputed by last observation carried forward ( LOCF ).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="336"/>
                <count group_id="O3" value="333"/>
                <count group_id="O4" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Summary Score (n=158, 336, 333, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4495" spread="0.5226"/>
                    <measurement group_id="O2" value="2.5498" spread="0.3610"/>
                    <measurement group_id="O3" value="4.5726" spread="0.3628"/>
                    <measurement group_id="O4" value="3.7964" spread="0.3575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Summary Score (n=158, 336, 333, 344)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0955" spread="0.5886"/>
                    <measurement group_id="O2" value="2.3221" spread="0.4065"/>
                    <measurement group_id="O3" value="2.8504" spread="0.4090"/>
                    <measurement group_id="O4" value="4.5142" spread="0.4026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Summary Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Summary Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Physical Summary Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Summary Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Summary Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mental Summary Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment (PatGA) of Disease Severity</title>
        <description>The Patient's Global Assessment of Disease Severity is a single-item patient reported outcome measure on which participants are asked to rate by circling a number on a 0 to 5 NRS the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been. LS mean change from baseline in patient's global assessment of disease severity score was calculated using (MMRM) with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned, and had baseline and at least 1 post baseline PatGA measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment (PatGA) of Disease Severity</title>
          <description>The Patient's Global Assessment of Disease Severity is a single-item patient reported outcome measure on which participants are asked to rate by circling a number on a 0 to 5 NRS the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been. LS mean change from baseline in patient's global assessment of disease severity score was calculated using (MMRM) with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned, and had baseline and at least 1 post baseline PatGA measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="339"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.09"/>
                    <measurement group_id="O2" value="-2.1" spread="0.06"/>
                    <measurement group_id="O3" value="-3.0" spread="0.06"/>
                    <measurement group_id="O4" value="-3.2" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75) or 100% (PPASI100) Improvement</title>
        <description>The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 75%, or of 100%, respectively, in the PPASI scores compared to baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants analyzed according to the treatment to which they are assigned; and who had palmoplantar Ps involvement at baseline. Participants who did not meet clinical response criteria or have missing data will be considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75) or 100% (PPASI100) Improvement</title>
          <description>The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 75%, or of 100%, respectively, in the PPASI scores compared to baseline.</description>
          <population>All randomized participants analyzed according to the treatment to which they are assigned; and who had palmoplantar Ps involvement at baseline. Participants who did not meet clinical response criteria or have missing data will be considered non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PPASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6"/>
                    <measurement group_id="O2" value="71.6"/>
                    <measurement group_id="O3" value="85.3"/>
                    <measurement group_id="O4" value="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9"/>
                    <measurement group_id="O2" value="61.1"/>
                    <measurement group_id="O3" value="80.4"/>
                    <measurement group_id="O4" value="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPASI 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5"/>
                    <measurement group_id="O2" value="50.5"/>
                    <measurement group_id="O3" value="69.6"/>
                    <measurement group_id="O4" value="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PPASI 50</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PPASI 50</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PPASI 50</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PPASI 75</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PPASI 75</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PPASI 75</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PPASI 100</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PPASI 100</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PPASI 100</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Ixekizumab Antibodies</title>
        <description>Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the # of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>All randomized participants who received at least 1 dose of study treatment and had evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Induction Period</title>
            <description>Placebo was administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W) up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>50 mg ETN - Induction Period</title>
            <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
          </group>
          <group group_id="O3">
            <title>Ixe Q4W - Induction Period</title>
            <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W; Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Ixe Q2W - Induction Period</title>
            <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Ixekizumab Antibodies</title>
          <description>Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the # of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%.</description>
          <population>All randomized participants who received at least 1 dose of study treatment and had evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="340"/>
                <count group_id="O4" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="14.1"/>
                    <measurement group_id="O4" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were summarized based on all randomized participants who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Induction Period</title>
          <description>Placebo was administered as 2 subcutaneous (SC) injections Q2W up through Week 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="E2">
          <title>50 mg ETN - Induction Period</title>
          <description>50 mg ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixe was administered as 2 SC injections at Week 0 followed by Placebo for ixe administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).</description>
        </group>
        <group group_id="E3">
          <title>Ixe Q4W - Induction Period</title>
          <description>160 mg ixe was administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection every 4 weeks (Q4W): (Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="E4">
          <title>Ixe Q2W - Induction Period</title>
          <description>160 mg ixe administered as 2 SC injections at Week 0 followed by 80 mg ixe as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.</description>
        </group>
        <group group_id="E5">
          <title>Ixe/Placebo- Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E6">
          <title>Ixe/Ixe Q12W - Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection every 12 weeks (Q12W) up to and including Week 56. To maintain blinding with Q4W dose regimen, Placebo for ixe given as 1 SC injection at every 4 weeks from Week 16 through Week 56.</description>
        </group>
        <group group_id="E7">
          <title>Ixe/Ixe Q4W - Maintenance Period Primary Pop</title>
          <description>Participants who received 80 mg ixe Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E8">
          <title>Placebo Resp/Placebo - Maintenance Period Secondary Pop</title>
          <description>Participants who received placebo during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E9">
          <title>Placebo Non-Resp/Ixe Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received placebo in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E10">
          <title>ETN Resp/Placebo Maintenance Period Secondary Pop</title>
          <description>Participants who received ETN during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E11">
          <title>ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop</title>
          <description>Participants who received ETN in Induction Period (Weeks 0 to 12) and classified as non-responders were administered 2 SC injections of placebo at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E12">
          <title>Ixe Q4W Non-Resp/Ixe Q4W- Maintenance Period Secondary Pop</title>
          <description>Participants who received 80 mg ixe Q4W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E13">
          <title>Ixe Q2W NonResp/Ixe Q4W Maintenance Period Secondary Pop</title>
          <description>Participants who received 80 mg ixe Q2W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixe as 1 SC injection and a Placebo for ixe injection at Week 12 followed by 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
        <group group_id="E14">
          <title>Ixe Q4W Maintenance Period Relapsed Pop</title>
          <description>Participants who relapsed (loss of response, sPGA ≥3 during Maintenance Period) were administered 80 mg ixe as 1 SC injection Q4W up to and including Week 56.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="350"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="200"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="6" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Mycobacterium tuberculosis complex test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="233"/>
              </event>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="357"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="347"/>
                <counts group_id="E4" subjects_affected="123" subjects_at_risk="350"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="176"/>
                <counts group_id="E6" subjects_affected="81" subjects_at_risk="181"/>
                <counts group_id="E7" subjects_affected="97" subjects_at_risk="187"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="75" subjects_at_risk="155"/>
                <counts group_id="E10" subjects_affected="41" subjects_at_risk="132"/>
                <counts group_id="E11" subjects_affected="97" subjects_at_risk="200"/>
                <counts group_id="E12" subjects_affected="27" subjects_at_risk="75"/>
                <counts group_id="E13" subjects_affected="23" subjects_at_risk="49"/>
                <counts group_id="E14" subjects_affected="120" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="357"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="347"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="350"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E14" events="5" subjects_affected="5" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E2" events="64" subjects_affected="18" subjects_at_risk="357"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="347"/>
                <counts group_id="E4" events="20" subjects_affected="12" subjects_at_risk="350"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E7" events="6" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="14" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="6" subjects_affected="5" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E2" events="192" subjects_affected="38" subjects_at_risk="357"/>
                <counts group_id="E3" events="30" subjects_affected="19" subjects_at_risk="347"/>
                <counts group_id="E4" events="74" subjects_affected="39" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="8" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E7" events="68" subjects_affected="15" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="42" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E10" events="5" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E11" events="82" subjects_affected="20" subjects_at_risk="200"/>
                <counts group_id="E12" events="21" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E14" events="60" subjects_affected="18" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="347"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="350"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E6" events="12" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="11" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E14" events="11" subjects_affected="11" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E2" events="40" subjects_affected="36" subjects_at_risk="357"/>
                <counts group_id="E3" events="40" subjects_affected="28" subjects_at_risk="347"/>
                <counts group_id="E4" events="35" subjects_affected="35" subjects_at_risk="350"/>
                <counts group_id="E5" events="23" subjects_affected="20" subjects_at_risk="176"/>
                <counts group_id="E6" events="31" subjects_affected="24" subjects_at_risk="181"/>
                <counts group_id="E7" events="42" subjects_affected="32" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="42" subjects_affected="29" subjects_at_risk="155"/>
                <counts group_id="E10" events="26" subjects_affected="20" subjects_at_risk="132"/>
                <counts group_id="E11" events="46" subjects_affected="34" subjects_at_risk="200"/>
                <counts group_id="E12" events="13" subjects_affected="12" subjects_at_risk="75"/>
                <counts group_id="E13" events="11" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E14" events="58" subjects_affected="39" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="347"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="7" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E13" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E14" events="12" subjects_affected="10" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="357"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="347"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E11" events="7" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="11" subjects_affected="11" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="357"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="347"/>
                <counts group_id="E4" events="21" subjects_affected="20" subjects_at_risk="350"/>
                <counts group_id="E5" events="19" subjects_affected="14" subjects_at_risk="176"/>
                <counts group_id="E6" events="23" subjects_affected="21" subjects_at_risk="181"/>
                <counts group_id="E7" events="30" subjects_affected="25" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="23" subjects_affected="20" subjects_at_risk="155"/>
                <counts group_id="E10" events="9" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E11" events="28" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E12" events="10" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E13" events="9" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E14" events="32" subjects_affected="21" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="357"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="347"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="350"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E7" events="9" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="14" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E14" events="5" subjects_affected="4" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Mycobacterium tuberculosis complex test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="357"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="347"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="350"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E7" events="10" subjects_affected="8" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="8" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E10" events="12" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E11" events="11" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E14" events="11" subjects_affected="10" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E7" events="10" subjects_affected="9" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="9" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E10" events="7" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E14" events="16" subjects_affected="12" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="357"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="357"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="347"/>
                <counts group_id="E4" events="22" subjects_affected="17" subjects_at_risk="350"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="176"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="181"/>
                <counts group_id="E7" events="13" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="14" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E10" events="13" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E11" events="17" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E13" events="7" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E14" events="13" subjects_affected="12" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="357"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="347"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="350"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="187"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E13" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E14" events="7" subjects_affected="7" subjects_at_risk="362"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

